Sana Biotechnology
Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.
Facts
- Sectors
- Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
-
Leadership or executive-pay change Apr 24, 2026
-
Leadership or executive-pay change Feb 17, 2026
-
Leadership or executive-pay change Sep 5, 2025
-
Leadership or executive-pay change Aug 29, 2025
-
Signed a material agreement Aug 7, 2025
-
Leadership or executive-pay change Oct 8, 2024
-
Leadership or executive-pay change Sep 12, 2024
-
Leadership or executive-pay change Apr 18, 2024
-
Signed a material agreement Feb 8, 2024
-
Leadership or executive-pay change Apr 28, 2023
-
Leadership or executive-pay change Apr 10, 2023
-
Signed a material agreement Jun 1, 2022
-
Signed a material agreement Jan 11, 2022
-
Signed a material agreement Oct 19, 2021
-
Leadership or executive-pay change Sep 3, 2021
-
Signed a material agreement Jul 14, 2021
-
Leadership or executive-pay change Mar 2, 2021
-
Filed to go public Jan 13, 2021
People
-
Steve Harr Co-founder and President and Chief Executive Officer
-
Snehal Patel Executive, Executive Vice President and Chief Technical Officer